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Suuunary--Chronic treatment of rats with haloperidol causes behavioral supersensitivity to dopaminergic 
agonists and an increase in the sensitivity of adenylate cyclase activity in the striatum to stimulation by 
dopamine. In this study the authors examined whether chronic treatment with haloperidol could elicit a 
change in sensitivity of adenylate cyclase in the striatum of the rat for guanyl nucleotides and the 
endogenous Ca 2+-binding protein, calmodulin. These agents increase the activation of adenylate cyclase 
activity by dopamine but act beyond the level of the dopamine receptor. Male, Sprague-Dawley rats were 
injected subcutaneously with either 0.6 mg/kg haloperidol or vehicle for 14 days. Four days after the last 
injection, the animals were sacrificed and the activity of adenylate cyclase was measured in a EGTA- 
washed particulate preparation of the striatum. There was an increase in the activation of adenylate cyclase 
activity by calmodulin and GppNHp but not by guanosine triphosphate (GTP) in particulate fractions 
of the striatum from rats treated with haloperidol as compared to controls. The sensitivity of adenylate 
cyclase to calmodulin was increased S-fold in particulate fractions from rats treated with haloperidol as 
opposed to vehicle-treated rats. The lack of change in activation by GTP was not due to an altered activity 
of GTPase in rats treated with haloperidol. In animals treated for 14 days but not withdrawn from 
haloperidol there was no statistically significant increase in the sensitivity of adenylate cyclase to 
calmodulin. There was no change in activation of the enzyme by GppNHp or GTP as compared to 
control. The activation of adenylate cyclase by calmodulin was not affected when haloperidol was added 
in vitro to the assay or after the acute injection of rats with haloperidol. 
These results demonstrate that the development of dopaminergic supersensitivity after withdrawal from 
chronic blockade of dopamine receptors resulted in increased sensitivity of post-receptor coupling 
mechanisms, as well as in changes in the receptor-mediated activity. In previous studies, increases in 
DA-stimulated adenylate cyclase activity were found with this treatment regimen. In this study it was 
shown that although basal activity was not changed, there was a selective increase in the sensitivity of 
adenylate cyclase to stimulation by calmodulin and GppNHp after chronic receptor blockade. These 
findings support previous observations suggesting a regulatory role for calmodulin in dopamine- 
stimulated adenylate cyclase activity. 
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The purpose of this study was to investigate further 
the role of calmodulin (CaM) in the regulation of 
dopamine (DA)-stimulated adenylate cyclase activity. 
Adenylate cyclase in the brain is activated by cal- 
modulin, a low-molecular weight calcium-binding 
protein (Brostrom, Brostrom and Wolff, 1978; 
Cheung Bradham, Lynch, Lin and Tallant, 1975). 
Several lines of evidence suggest a role for calmodulin 
in modulating dopaminergic activity (Gnegy, Lau 
and Treisman, 1980). Striatal membranes from rats 
exhibiting behavioral supersensitivity to DA after 
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withdrawal from chronic treatment with haloperidol 
had an increased content of calmodulin and increased 
activity of DA-sensitive adenylate cyclase (Gnegy, 
Lucchelli and Costa, 1977a; Gnegy, Uzunov and 
Costa, 1977b). Hanbauer, Pradham and Yang (1980) 
reported that membranes prepared from slices of 
striatum, treated with amphetamine contained de- 
creased activity of DA-sensitive adenylate cyclase and 
decreased content of calmodulin as compared to 
controls. Calmodulin activates basal activity of 
adenylate cyclase in striatal membranes from the rat 
and increases the sensitivity of the enzyme for DA 
3-4fold (Gnegy and Treisman, 1981). Several in- 
vestigators have found two components of the activ- 
ity of adenylate cyclase in the brain of the rat, 
including the striatum, one of which is sensitive to 
stimulation by calmodulin and one of which is insen- 
sitive to calmodulin (Brostrom, Brostrom and Wolff, 
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1977; Heideman, Wierman and Storm, 1982; Tre- 
isman, Bagley and Gnegy, 1983). Previous studies 
suggested that calmodulin-sensitive adenylate cyclase 
activity in the striatum of the rat was activated by 
guanyl nucleotides, preferentially by small concen- 
trations of the non-hydrolyzable analog, guanosine 
triphosphate (GTP), guanosine-S-(fl,y -imido)- 
triphosphate (GppNHp; Treisman et al., 1983). 
Chronic treatment of rats with a DA antagonist 
such as haloperidol has been used as a model for 
Parkinson’s disease (Hornykiewicz, 1973, 1975). 
After withdrawal from chronic treatment with halo- 
peridol, rats exhibit an increased behavioral sensi- 
tivity to DA agonists (Christensen, Fjalland and 
Msller Nielsen, 1976; Klawans and Rubovits, 1972; 
Sayers, Biirki, Ruth and Asper, 1975; Tarsy and 
Baldessarini, 1974). In striatal membranes from rats 
treated chronically with haloperidol, increases in the 
binding of [3H]haloperidol, a measure of binding to 
DA D-2 receptors (Burt, Creese and Snyder, 1977) 
and the activity of DA-stimulated adenylate cyclase, 
a measure of the activity of DA D-l receptors 
(Marshall and Mishra, 1980; Gnegy et al., 1977a, b; 
Iwatsubo and Clouet, 1975) have been reported. 
These changes reflect a change in dopaminergic activ- 
ity at the level of the receptor. 
In this study, the authors wished to determine 
whether the supersensitivity could be expressed 
through agents which affect dopaminergic stimu- 
lation, yet activate adenylate cyclase at a level beyond 
the receptor. The effect of chronic treatment with 
haloperidol on the activation of adenylate cyclase by 
calmodulin, as well as by GTP and GppNHp, which 
activate adenylate cyclase by binding to an activating 
guanyl nucleotide-binding protein termed N, 
(Rodbell, 1980; Limbird, 1981) was examined. It was 
found that the activity of adenylate cyclase had an 
increased sensitivity to both calmodulin and 
GppNHp but no change in sensitivity to GTP as 
compared to vehicle-treated controls. The lack of 
change in stimulation by GTP was not due to an 
increase in hydrolysis of GTP elicited by the treat- 
ment with haloperidol. These results demonstrate 
that chronic treatment with haloperidol can increase 
the sensitivity of adenylate cyclase to factors which 




Male, Sprague-Dawley rats Strain Crl: CD(SD)BR 
(206250g) were obtained from Charles River 
Breeding Laboratories, Wilmington, Massachusetts, 
U.S.A. The rats were injected for 14 days with 
0.6 mg/kg (s.c.) of haloperidol or 0.1 ml/O.1 kg of a 
vehicle consisting of 0.9% saline solution containing 
5 PI/ml of ethanol and 5 PI/ml glacial acetic acid. A 
similar regimen has been shown to result in increased 
stereotyped behavior in rats after a challenge with 
apomorphine (Gnegy et al., 1977a). In some experi- 
ments, rats were withdrawn from the drug for 4 days 
before sacrifice. Rats not withdrawn from the drug 
were killed 1 hr after the last injection. Acute treat- 
ments consisted of a single injection of the above 
solutions 1.5 hr prior to decapitation. 
Preparation of particulate fraction 
Particulate fractions of striatum were prepared 
as described by Brostrom et al. (1978). Briefly, rats 
were killed by decapitation, the striata were removed 
and homogenized in 9 vol of 10mM Tris maleate 
buffer, pH 7.5 containing 1 mM mgS0, and 1.2 mM 
ethylene glycol bis @-aminoethyl ether)-N,N,N’,N’- 
tetraacetic acid (EGTA). The homogenate fraction 
was centrifuged at 27,000 g for 20 min and the re- 
sulting pellet was resuspended in 9 vol of the above 
buffer and centrifuged a second time. The pellet 
resulting from the final centrifugation was re- 
suspended in the above buffer to a concentration of 
approx. 5 mg of protein/ml. Protein content was 
determined by the method of Lowry, Rosebrough, 
Farr and Randall (1951). 
Assay of adenylate cyclase 
The activity of adenylate cyclase was measured in 
an assay (200 ~1 volume) containing: 80 mM Tris 
maleate buffer, pH 7.5, 5 mM MgSO,, 2 mM CAMP, 
4 mM phosphoenolpyruvate, 20 pg pyruvate kinase, 
0.12 mM isobutylmethylxanthine, 100-150 pg of par- 
ticulate membrane protein, 0.15 mM EGTA and 
1 mM [x-~~P]ATP (1 PCi per assay) with or without 
additions such as GppNHp, GTP, CaCl, and cal- 
modulin. Assays were incubated for 10 min and the 
reaction was stopped by heating for 1 min at 95°C. A 
solution (200 ~1) containing 20 mM ATP and 0.7 mM 
CAMP was then added to the tubes. The particulate 
material was centrifuged and 32P-labelled CAMP in 
the supernatant fraction was determined by the 
method of Krishna, Weiss and Brodie (1968). Recov- 
ery of the CAMP was measured using the [3H]cAMP 
and was usually 8&90%. Free or effective concen- 
trations of Ca2+ were calculated using a dissociation 
constant for Ca2+ EGTA of 4.08 x lOma M according 
to the method of Nanninga and Kempen (1971). 
Assay of GTPase 
The activity of GTPase was assayed using 
[Y-~~P]GTP according to the method of Cassel, 
Levkovitz and Selinger (1977). Assay contents, 
modified to be more similar to those of the 
adenylate cyclase assay in a volume of 100 ~1, were: 
12.5 mM Tris HCl buffer, pH 7.5, 5 mM MgCl,, 
1 mM ATP, 1 mM adenosine-5’-(/?,y-imido)triphos- 
phate (AppNHp), 1 mm creatine phosphate, 5 U 
creatine phosphokinase, 1 mM ouabain, 2mM 
dithiothreitol, 5 pg membrane protein, 150 PM and 
50,000 cpm of [y-s2P]GTP plus various additions such 
as nonradioactive GTP, Ca*+ and CaM. Incubations 
were conducted for 10 min at 37°C. Assays were 
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Fig. 1. Activation of the activity of adenylate cyclase by 
calmodulin (CaM) in particulate fractions from the striatum 
of rats chronically treated with haloperidol (A.) or vehicle 
(0) and withdrawn for 4 days. Activity of adenylate cyclase 
was measured in EGTA-washed striatal particulate frac- 
tions as described in Methods. Assays contained 0.12pM 
free Ca*+ (1OOpM added CaClJ. Each point represents 
the average value from five different animals + SEM. 
*P < 0.05; **P 5 0.02. Inset: Results expressed as a Hanes 
plot with substrate (s) on the abscissa and substrate/velocity 
(s/v) on the ordinate. Kinetic constants from this form of 
analysis are shown in Table 1. 
terminated and free 32Pi determined as described by 
Cassel et al. (1977). The activity of the low K, 
GTPase can be closely approximated by correcting 
for the hydrolysis of GTP by a high K, activity of 
nucleoside triphosphate (Cassel et al., 1977). In the 
present experiments, low K, activity of GTPase was 
calculated as the difference between the number of 
counts per minute of 32Pi released in the absence and 
presence of 100pM GTP. 
Preparation and measurement of calmodulin 
Calmodulin was purified from bovine brain using 
phenylsepharose chromatography and DEAE- 
cellulose chromatography by a modification of the 
methods of Dedman, Potter and Means (1977) and of 
Gopalkrishna and Anderson (1982). The calmodulin 
demonstrated a single band on disc gel electro- 
phoresis containing 10% polyacrylamide. Cal- 
modulin was prepared in the presence of millimolar 
concentrations of EGTA, dialyzed against 0.05 M 
(NH,)HCO, and lyophilized. The calmodulin was 
redissolved in 10 mM Tris maleate buffer, pH 7.5. 
The M, determined by slab gel electrophoresis using 
standards of known molecular weight was 
16,200 daltons. Calmodulin was measured by its abil- 
ity to activate calmodulin-depleted preparations of 
bovine brain 3’S’-cyclic-AMP phosphodiesterase 
(PDE) using purified calmodulin as a standard 
(Gnegy, Nathanson and Uzunov, 1977c). Cal- 
modulin-activated PDE was prepared as described by 
Klee and Krinks (1978). 
Statistics 
Statistical differences were analyzed using an un- 
paired Student’s t-test. 
Materials 
Haloperidol was a generous gift from McNeil 
Laboratories, Inc. (Fort Washington, Pennsylvania, 
U.S.A.); [ac-‘*P]ATP (sp. act. 10-30 Ci/mmol), 
[Y-~*P]GTP (sp. act. 20-40Ci/mmol) and [3H]cAMP 
(sp. act. 20-30 Ci/mmol) were purchased from 
Amersham Searle. Phosphoenolypyruvate, AppNHp, 
AMP and ATP were obtained from Sigma Chemical 
Co.; pyruvate kinase was from Boehringer 
Mannheim. Both GTP and GppNHp (high pressure 
liquid chromatography purified) were purchased 
from International Chemical and Nuclear Corp. All 
other materials and reagents were the highest com- 
mercially available grade produced. 
RESULTS 
Activation of the activity of adenylate cyclase by 
calmodulin in particulate fractions of the striatum from 
rats withdrawn from chronic treatment with vehicle or 
haloperidol 
Activation of the activity of adenylate cyclase by 
various concentrations of calmodulin was measured 
in particulate fractions of the striatum from rats 
treated with haloperidol or vehicle. As shown on the 
ordinate of Fig. 1, basal activity of adenylate cyclase 
did not significantly differ in the two groups. Cal- 
modulin stimulated formation of CAMP to a greater 
extent in particulate fractions from animals treated 
with haloperidol than from controls at concen- 
trations up to 250 nM (Fig. 1). The activation of 
adenylate cyclase by calmodulin, however, did not 
differ significantly between the two groups at concen- 
trations greater than 1 PM calmodulin. The activity 
of adenylate cyclase from rats treated with halo- 
peridol, however, had a greater sensitivity to cal- 
modulin than did that from vehicle-treated rats. 
Kinetic analysis of the data using a Hanes plot (insert 
Fig. 1) revealed a 4.7-fold increase in sensitivity of 
adenylate cyclase for calmodulin in membranes from 
rats treated with haloperidol as compared to vehicle 
with no change in maximum response. The apparent 
kinetic constants determined using Hanes analysis for 
the two groups are given in Table 1. The apparent K, 
for calmodulin was significantly decreased almost 
S-fold from 76 nM in fractions from vehicle-treated 
rats to 16 nM in fractions from rats treated with 
haloperidol. The apparent V,,,,, did not change as a 
result of treatment with drug and was 116 and 
115 pmol/min per mg protein in fractions from 
vehicle and haloperidol-treated rats, respectively. 
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Table I Apparent kinetic constants for activation of adenylate q&se hy calmodulin (GM) 
in rats treated chronically with haloperidol or vehicle 
Apparent kinetic constants* 
Withdrawn Non-withd&+m 
-~- ---- _-. 
Treatmentt KS&w Y”..! K? V”pP 
Vehicle 76ri: 13 116?r15 60_+ 12 131ilI 
Haloperidol 16If:3$ 115 rf: IO 33 +4 1 IO f 10 
*Apparent kinetic constants (app) were determined by Hanes analysis of the data presented 
in Fig. I (withdrawn from drugs) and Fig. 3 (non-withdrawn from drugs). The apparent 
K,‘s are given in nM and apparent V,,, ‘s in pmof/min per mg protein. Values are given 
&SEM for 5 different animals in each group. 
tRats were injected for 14 days with 0.6 mg/kg of haloperidol (SC.), or 0. I ml/O. Ikg of a 
vehicle consisting of 0.9% vehicle solution containing 5 PI/ml of ethanol and 5 rl/ml 
glacial acetic acid. Rats were withdrawn from the drug for 4 days before sacrifice. Rats 
not withdrawn from the drug were killed 1 hr after the last injection. 
$P < 0.001 as compared to value for vehicle-treated animals. 
The change in sensitivity to calmodulin was not 
due to a difference in endogenous content of cal- 
modulin in the particulate fractions of striatum from 
rats treated with haloperidol or vehicle. The calmod- 
ulin content in the EGTA-washed particulate frac- 
tions of striatum from rats treated with vehicle and 
haloperidol was 2.5 _+ 0.4 and 2.5 _+ 0.3 ng CaM/pg 
membrane protein, respectively; EGTA reduced the 
concentration of calmoduljn in striatal membranes by 
over 50% but did not remove all of the endogenous 
calmodulin. 
Ac~iz?atian of adeny~are c_vclase by GppNHp and GTP 
in particulate fractions of striatum from rats with- 
drawn from chronic treatment with vehicle or halo- 
peridol 
The stimulation of the activity of adenylate cyclase 
from the striatum by GTP and the non-hydrolyzable 
analog of GTP, GppNHp was examined. As shown 
in Fig. 2, the activity of adenylate cyclase in striatal 
membranes from rats treated chronically with halo- 
peridol was significantly more sensitive to stimulation 
by GppNHp than that from controls. Maximal stim- 
ulation by the nucleotide occurred at 100pM 
GppNHp and was not different in fractions from 
animals treated with vehicle or haloperidol. The EC& 
for GppNHp, the effective concentration which pro- 
vided 50% of the maximal activation, was 0.5 PM in 
the fractions from rats treated with vehicle and 
0.08 PM in fractions from rats treated with halo- 
peridol. On the contrary, the results in Table 2 
demonstrate that no differences were found in the 
response of adenylate cyclase to GTP in striatal 
fractions from animals treated with vehicle or halo- 
peridol. The response to GTP was biphasic and a 
maximal response occurred at 1 PM GTP, as shown 
previously (Treisman et al., 1983). 
Activation of adenytate cyclase by ~almaduiin, GTP 
and GppNHp in animals treated chronicaliy with halo- 
peridol or vehicle and not withdrawn from the drugs 
before sacrifice 
In order to assess whether the increased response 
to calmodulin and GppNHp in membranes from the 
striatum of rats withdrawn from treatment with 
haloperidol, as opposed to vehicle, was due to a 
compensatory response to continued receptor block- 
ade, the activation of adenylate cyclase by calmodulin 
and by guanyl nucleotides in striata from rats not 
withdrawn from the drugs was examined. Male, 
Sprague-Dawiey rats were treated for 14 days with 
halo~ridol or vehicle as described in Methods but 
were sacrificed 1 hr after the last injection. As shown 
in Fig. 3, the activity of adenylate cyclase in particu- 
late fractions from the striatum of animals chroni- 
cally treated with haIope~do1 was not significantly 
0 0.01 0.1 1 10 100 
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Fig. 2. Activation of the activity of adenyiate cyclase by 
GppNHp in particulate fractions from the striatum OF rats 
chronically treated with haloperidol (A) or vehicle (0) and 
withdrawn for 4 days. The activity of adenylate cyclase was 
measured in EGTA-washed striata! particulate fractions as 
described in Methods. Each point represents the average 
value from five different animals i SEM. *P 5 0.05. 
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Table 2. Activation of adenylate cyclase by GTP in particulate 
fractions from the striatum of animals chronically treated with 









Adenylate cyclase activity 
Vehicle Haloperidol’ 
(pmol/min per mg protein) 
83 +_ 3 75 + 3 
123 *7 116+8 
179*9 176 f IO 
156+9 l58f9 
158 +23 I51 + I4 
*Rats were treated with haloperidol or vehicle as described in 
Table I. Results are given +SEM for N = 5. 
different from controls. The overall activity of 
adenylate cyclase was slightly but not significantly 
decreased in the particulate fractions from rats 
treated, but not withdrawn from, haloperidol as 
compared to controls. Although the absolute re- 
sponse values were slightly decreased with calm- 
odulin, there was a 2-fold increase in sensitivity to 
calmodulin in the particulate fractions from rats 
treated with haloperidol as compared to controls. 
Apparent kinetic constants for the activation of 
adenylate cyclase by calmodulin in the two groups are 
given in Table 1. The change in sensitivity for 
calmodulin in the non-withdrawn animals was not 




Fig. 3. Activation of the activity of adenylate cyclase by 
calmodulin (CaM) in animals treated chronically with halo- 
peridol (A) or vehicle (0) and sacrificed 1 hr after the last 
injection. The activity of adenylate cyclase was measured in 
EGTA-washed particulate fractions as described in Meth- 
ods. Assays contained 0.12 PM free Ca2+ (100 PM added 
CaCI,). Each point represents the average value from five 
different animals k SEM. Inset: Results expressed as a 
Hanes plot with substrate (s) on the abscissa and 
substrate/velocity (s/v) on the ordinate. Kinetic constants 
from this form of analysis are shown in Table 1. 
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Table 3. Activation of adenylate cyclase by guanyl nucleotides and 
DA in striata from rats chronically treated with vehicle or halo- 
peridol and sacrificed I hr later 
Adenylate cyclase activity 
Addition Concentration Vehicle Haloperidol* 
to assay (FM) (pmol/min per mg protein)? 
None 95 f 5 91 f8 
GPPNHP 0.1 128 f 12 131 f 12 
I.0 189 f 12 196 + 12 
10.0 267 f 6 272 f 16 
100.0 311 f II 309 f 12 
GTP 0.1 121 f 9 131 + I2 
1.0 215 ?9 207 f 13 
DAf I 27 + 2 7* I§ 
50 90 f 9 lOBi 
*Rats were treated for 14 days with vehicle or haloperidol as 
described in Methods and Table I and killed I hr after the last 
injection. Adenylate cyclase activity was measured in EGTA- 
washed particulate fractions as described in Methods. 
tResults are given+SEM for N = 5. 
iAssays containing DA also contained I PM GTP since GTP is 
required to detect activation by DA in these washed fractions. 
Results are given as the pmol of cAMP/min per mg protein 
produced by DA above that produced by 1 PM GTP. 
BP 10.05 as compared to the value for vehicle-treated rats. 
withdrawn from haloperidol. These results suggest 
that, in the same manner as the change in sensitivity 
to DA, the increased activation by calmodulin be- 
came more apparent after withdrawal of the drug. 
Table 3 shows the data for activation of adenylate 
cyclase from the striatum by GTP, GppNHp and DA 
in fractions from the striatum of rats chronically 
treated with vehicle or haloperidol, but not with- 
drawn from the drugs before sacrifice. No significant 
differences in activation by GTP or GppNHp were 
found between the two groups. Activation of 
adenylate cyclase by a submaximal concentration of 
DA was decreased in striatal particulate fractions 
from rats treated with haloperidol as compared to 
controls, suggesting that haloperidol was still present 
in the membranes and blocking activation by DA. 
EfSect of haloperidol, administered acutely, on the 
activation of adenylate cyclase from the striatum of the 
rat by calmodulin 
The effect of an acute treatment with haloperidol 
on the activity of adenylate cyclase and the activation 
by calmodulin was examined. The authors wished to 
determine further whether treatment with haloperidol 
directly affected the activation of adenylate cyclase by 
calmodulin. Rats were treated with either 0.6 mg/kg 
haloperidol subcutaneously or an equal volume of 
vehicle and sacrificed 1.5 hr later. The activation of 
adenylate cyclase by calmodulin and DA was deter- 
mined in particulate fractions from the striatum of 
rats treated with haloperidol or vehicle. As shown in 
Table 4, there was no significant difference in the 
activity of adenylate cyclase between fractions from 
rats treated with haloperidol or vehicle. Similarly, the 
responsiveness to calmodulin in terms of percentage 
stimulation of basal activity was not significantly 
different between the two groups. The haloperidol 
present in the striatum after injection did block DA 
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Table 4. Activation of adenylate cyclase by calmodulin (CaM) and 
DA in striata from rats treated acutely with haloperidol or vehicle 
Adenylate cyclase activity 
Addition Vehicle Haloperidol* 
to assay Concentration (pmol/min per mg protein)t 
None 117*9 114+13 
CaM 28 nM I58 2 I4 135 i I6 
140 nM 194 i I9 167 i_ I4 
280 nM 215+23 192 k 32 
1400 nM 226 f 30 230 + 20 
DAf lpM 41 i 7 8& 8§ 
50/1M 93 + 8 llE+ll 
‘Male Sprague-Dawley rats were injected with either 0.6 mg/kg (s.c.) 
haloperidol or an equal volume of vehicle and sacrificed I.5 h 
later. The activity of adenylate cyclase was measured in EGTA- 
washed striatal particulate fractions as described in Methods. 
Assays containing calmodulin (CaM) also contained IOOpM 
CaCI, (0.12pM free Ca2+). 
tResults are given f standard error of the mean, N = 3. 
fDopamine (DA)-stimulated activity was determined as described in 
Table I. Adenylate cyclase activity in the presence of I PM GTP 
was 285 k 30 and 220 f 9 pmol/min per mg protein in particu- 
late fractions from the striatum from vehicle and haloperidol- 
treated rats, respectively. 
@P < 0.01 as compared to the value for vehicle-treated rats. 
receptors as shown by the decrease in activation of 
adenylate cyclase by 1 pm DA in striata from rats 
treated with haloperidol as compared to controls 
(Table 4). 
Haloperidol added to particulate fractions of stri- 
atum in vitro did not decrease the basal activity of 
adenylate cyclase until concentrations of 10 PM were 
attained (data not shown). Similarly, haloperidol in 
vitro did not inhibit activation by calmodulin until 
concentrations of 10 PM were reached, even when 
haloperidol was preincubated with the membranes 
for 5-10min at 37°C. 
The activity of GTPase in particulate fractions from 
the striatum of rats treated chronically with haloperidol 
or vehicle 
The results have shown that adenylate cyclase in 
particulate fractions from the striatum of rats with- 
drawn from chronic treatment with haloperidol had 
an increased sensitivity to GppNHp but not to GTP. 
An increase in the activity of GTPase in striatal 
particulate fractions from rats treated with halo- 
peridol could negate possible increases in activation 
of GTP. The hydrolysis of lo-‘M GTP was mea- 
sured in particulate fractions from the striatum of 
animals treated with drug and control animals. This 
concentration was near the apparent K, for the low 
K, for GTPase related to adenylate cyclase in mem- 
branes (Cassel and Selinger, 1976; Koski and Klee, 
1981). No change was found in activity of GTPase in 
particulate fractions from the striatum of rats treated 
with vehicle or haloperidol withdrawn from treat- 
ment 4 days, being 24.2 + 1.5 and 23.7 + 
1.5 pmol/min per mg protein, respectively. Similarly, 
there was no significant change in hydrolysis of 
lo-‘M GTP in particulate fractions from the stri- 
atum of rats not withdrawn from vehicle and halo- 
peridol, being 24.3 k 1.7 and 21.7 & 1 .O pmol/min per 
mg protein, respectively. 
Activation of adenylate cyclase by dopamine in partic- 
ulate fractions from the striatum of rats withdrawn 
from chronic treatment with vehicle or haloperidol 
It has previously been demonstrated that activity 
of adenylate cyclase in particulate fractions from the 
striatum of rats chronically treated with haloperidol 
was 34-fold more sensitive to DA than that from 
controls (Gnegy et al., 1977b). To confirm that the 
animals used in the present studies were super- 
sensitive to DA, the activation of adenylate cyclase 
by 1 and 50pM DA was examined in the striatum 
from drug-treated and control animals. The apparent 
K, of adenylate cyclase for DA in this particulate 
preparations was approx. 1 p M. Fifty micromoles of 
DA represents a maximal activating concentration 
(Gnegy and Treisman, 1981). The activation of ade- 
nylate cyclase by 1 PM DA was significantly greater 
in particulate fractions from rats treated with halo- 
peridol as compared to controls, being 40 f 6 and 
24 f 3 pmol/min per mg protein, respectively (N = 5, 
P < 0.05 for haloperidol-treated as compared to 
vehicle-treated fractions). The amount of CAMP pro- 
duced by 50 PM DA was the same in fractions from 
rats treated with vehicle and haloperidol, 93 k 7 and 
88 f 11 pmol/min per mg protein, respectively. 
DISCUSSION 
Rats withdrawn from chronic treatment with neu- 
roleptic drugs, such as haloperidol, exhibit behavioral 
supersensitivity to DA agonists. Increased activity 
of DA receptors has been demonstrated neuro- 
chemically in the striatum of the rat by an increase 
in the binding of [3H]haloperidol (Burt et al., 1977) as 
well as an increase in the sensitivity of adenylate 
cyclase to DA (Gnegy et al., 1977a. b). The results of 
this study demonstrate that adenylate cyclase in the 
striatum developed a heightened sensitivity for agents 
acting beyond the receptor as a result of chronic 
treatment with antipsychotic drugs. Previous studies 
demonstrated that there was a 34-fold decrease in 
the apparent K, for activation by DA of adenylate 
cyclase in membranes from the striatum of rats 
treated chronically and withdrawn from haloperidol 
as compared to vehicle-treated controls (Gnegy et al., 
1977a). A 5-fold increase in the sensitivity of 
adenylate cyclase in the striatum for calmodulin and 
a 6-fold increase in sensitivity for GppNHp in mem- 
branes from the striatum of rats chronically treated 
with haloperidol has now been demonstrated. This 
represents a large kinetic change as a result of chronic 
treatment with neuroleptics and would result in a 
large increase in the activation of adenylate cyclase by 
these agents in vivo. 
Calmodulin has been shown to increase the sensi- 
tivity of adenylate cyclase in the striatum for DA and 
thus to play a role in regulating sensitivity to DA 
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(Gnegy and Treisman, 1981). The exact mechanism 
by which calmodulin activates adenylate cyclase is 
not known. Studies have suggested that it acts 
directly at the catalytic subunit (Salter, Krinks, Klee 
and Neer, 1981) and does not require GTP for its 
activity (Heideman et al., 1982; Seamon and Daly, 
1982). Calmodulin has been shown to increase the 
activation of adenylate cyclase by DA in the striatum 
(Gnegy and Treisman, 1981) and retina (Gnegy, 
Muirhead and Harrison, 1984) and fl-adrenergic 
receptor activation of adenylate cyclase in the cere- 
bellum (Malnoe, Stein, and Cox, 1983). Calmodulin 
can increase the sensitivity for guanyl nucleotides of 
the calmodulin-sensitive adenylate cyclase in the cere- 
bral cortex (Brostrom et al., 1978). It is possible that 
calmodulin could act at the catalytic subunit in such 
a manner as to increase the association between the 
guanyl nucleotide binding protein and the catalytic 
subunit. 
Activation of adenylate cyclase by hormones is 
mediated by a GTP-binding protein termed N, con- 
sisting of GI, /3 and y subunits. Guanyl nucleotides 
bind to the CI subunit of N,, which is a 45,000 dalton 
protein that mediates the activation of adenylate 
cyclase (Manning and Gilman, 1983). An increase in 
sensitivity of adenylate cyclase to GppNHp suggests 
that there could be a change in affinity of N, for 
guanyl nucleotides or a higher affinity for coupling of 
N, with the catalytic subunit as a consequence of 
supersensitivity. A decrease in coupling of receptor- 
adenylate cyclase systems through the guanyl nucleo- 
tide binding protein has been reported to result from 
ligand-mediated desensitization in cell lines (Harden, 
Su and Perkins, 1979). Receptor-coupled inhibition 
of the activity of adenylate cyclase is mediated by 
another GTP-binding protein, Ni, that also consists 
of CI, p and y subunits (Murayama and Ui, 1983; 
Hildebrandt, Sekura, Codina, Iyengar, Manclark and 
Birnbaumer, 1983). Activation of DA D-2 receptors 
has been shown to be mediated through Ni and 
results in attenuation of adenylate cyclase activity in 
the pituitary gland (Cote, Grewe and Kebabian, 
1981) and striatum (Stoof and Kebabian, 1981). 
Although the present studies have been directed 
toward investigating the activation of adenylate 
cyclase by DA (D-l receptor activity) through N,, the 
increased GppNHp activation could represent a 
decrease in Ni activity. 
However, chronic treatment with haloperidol did 
not alter the response of adenylate cyclase in the 
striatum to GTP. The lack of change in stimulation 
by GTP could not be attributed to a significant 
alteration in GTPase activity in the membranes from 
the striatum of rats treated with haloperidol. Previous 
work suggests that GTP, in the absence of DA, is 
activating a separate component of adenylate cyclase 
from that of small concentrations of GppNHp 
(Treisman et al., 1983). A kinetic analysis of the data 
demonstrated two components of the activity of 
adenylate cyclase in the striatum of the rat. One 
component was activated by calmodulin and concen- 
trations of GppNHp below 1 PM. The other com- 
ponent was activated by GTP and larger concen- 
trations of GppNHp. The results attained in this 
study suggest that chronic treatment with haloperidol 
induces an alteration in the calmodulin-sensitive 
component of adenylate cyclase which may be inde- 
pendent of the GTP-activated component. It has 
similarly been demonstrated that when the sensitivity 
of adenylate cyclase to DA in retina is modified by 
light, then the sensitivity of the enzyme to calmodulin 
and GppNHp, but not to GTP, is altered (Gnegy et 
al., 1984). 
The increase in sensitivity to calmodulin and 
GppNHp is most likely to be a compensatory super- 
sensitivity resulting from chronic receptor blockade. 
There was no change in stimulation by GppNHp or 
GTP and no significant change in activation by 
calmodulin in particulate fractions from the striatum 
of rats treated with haloperidol and not withdrawn 
from the drug, as compared to control. The increase 
in sensitivity to calmodulin could develop during 
chronic treatment with drugs but is most apparent 
when the drug is withdrawn. The reason that the 
sensitivity to GppNHp and calmodulin did not 
change prior to withdrawal is not clear. It is possible 
that the interaction between the dopamine receptor 
and N, is altered during chronic blockade, and it is 
only after withdrawal that the increased sensitivity 
of adenylate cyclase to actions mediated by N, or 
calmodulin are seen. The changes in sensitivity to 
calmodulin parallel the response of adenylate cyclase 
to DA. Results from the present studies, using acute 
treatment with haloperidol or in vitro addition to 
striatal membranes demonstrated that haloperidol 
did not directly inhibit activation of adenylate cyclase 
by calmodulin. Antipsychotic drugs, such as 
trifluoperazine, have been shown to bind to cal- 
modulin and prevent it from activating target 
enzymes (Levin and Weiss, 1977). Haloperidol is 
much weaker in its binding to calmodulin than 
trifluoperazine and might not be expected to inhibit 
the activity of calmodulin by directly inhibiting acti- 
vation of adenylate cyclase at smaller concentrations 
(Weiss, Prozialeck, Cimino, Barnette and Wallace, 
1980). The present results suggest that the increased 
responsiveness to calmodulin after withdrawal from 
chronic treatment with haloperidol is a consequence 
of chronic blockade of DA receptors as opposed to 
a release from continued direct inhibition of cal- 
modulin. 
In conclusion, the sensitivity of adenylate cyclase 
from the striatum of the rat to stimulation by cal- 
modulin and GppNHp was increased after with- 
drawal from chronic treatment with haloperidol sug- 
gesting an increase in the coupling of DA receptors 
to adenylate cyclase. The supersensitivity, developed 
to these agents, may be a compensatory response to 
continued receptor blockade since the increased re- 
sponse was not detected in rats treated acutely with 
594 G. J. TREISMAN et al 
the drug. The increase in sensitivity to calmodulin Gnegy M. E., Lau Y. S. and Treisman G. (1980) Role of 
and GppNHp correlated with an increase in sensi- 
tivity of adenylate cyclase to DA and appears to 
reflect an increase in the calmodulin-sensitive com- 
ponent of adenylate cyclase. These results demon- 
strate that neurochemical changes occurring as a 
result of chronic blockade of DA receptors can 
develop at a level beyond that of the receptor itself 
and can be reflected in the coupling mechanism of the 
receptor as well as at the receptor itself. 
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